SINCO PHARMA Announces Interim Results: Shareholders' Profit Dips 18.37% to RMB 19.9 Million

Stock News08-28

SINCO PHARMA (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to shareholders of the company stood at RMB 19.909 million, reflecting a decline of 18.37% compared to the same period last year, with earnings per share at RMB 0.0098.

In line with the reduction in group revenue, the gross profit for the reporting period decreased by RMB 6.6 million to RMB 124 million, compared to RMB 130.7 million for the six months ended June 30, 2025. Despite this, the gross profit margin improved from 10.9% to 12.0%, driven by lower procurement costs and a stronger Renminbi against the US dollar, which reduced the cost of sales.

These figures highlight the company's ongoing operational adjustments amid challenging market conditions, while the margin expansion signals improved cost efficiency despite the top-line contraction.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184962434?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-28 17:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184962434","market":"sh","top_or_hot":-1,"title":"SINCO PHARMA Announces Interim Results: Shareholders' Profit Dips 18.37% to RMB 19.9 Million","media":"Stock News","content":"<p><b>SINCO PHARMA</b> (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to shareholders of the company stood at RMB 19.909 million, reflecting a decline of 18.37% compared to the same period last year, with earnings per share at RMB 0.0098.<br><br>In line with the reduction in group revenue, the gross profit for the reporting period decreased by RMB 6.6 million to RMB 124 million, compared to RMB 130.7 million for the six months ended June 30, 2025. Despite this, the gross profit margin improved from 10.9% to 12.0%, driven by lower procurement costs and a stronger Renminbi against the US dollar, which reduced the cost of sales.<br><br>These figures highlight the company's ongoing operational adjustments amid challenging market conditions, while the margin expansion signals improved cost efficiency despite the top-line contraction.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SINCO PHARMA Announces Interim Results: Shareholders' Profit Dips 18.37% to RMB 19.9 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSINCO PHARMA Announces Interim Results: Shareholders' Profit Dips 18.37% to RMB 19.9 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-28 17:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>SINCO PHARMA</b> (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to shareholders of the company stood at RMB 19.909 million, reflecting a decline of 18.37% compared to the same period last year, with earnings per share at RMB 0.0098.<br><br>In line with the reduction in group revenue, the gross profit for the reporting period decreased by RMB 6.6 million to RMB 124 million, compared to RMB 130.7 million for the six months ended June 30, 2025. Despite this, the gross profit margin improved from 10.9% to 12.0%, driven by lower procurement costs and a stronger Renminbi against the US dollar, which reduced the cost of sales.<br><br>These figures highlight the company's ongoing operational adjustments amid challenging market conditions, while the margin expansion signals improved cost efficiency despite the top-line contraction.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1184962434","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184962434","pubTimestamp":1787908817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SINCO PHARMA (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06833":"兴科蓉医药","BK1197":"保健护理产品经销商"},"translate_title":"新科医药公布中期业绩：股东利润下降18.37%至1990万元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"SINCO PHARMA (06833) has released its interim results for the six months ended June 30, 2026, reporting a revenue of RMB 1.032 billion, a decrease of 13.66% year-on-year. Profit attributable to shareholders of the company stood at RMB 19.909 million, reflecting a decline of 18.37% compared to the same period last year, with earnings per share at RMB 0.0098.In line with the reduction in group revenue, the gross profit for the reporting period decreased by RMB 6.6 million to RMB 124 million, compared to RMB 130.7 million for the six months ended June 30, 2025. Despite this, the gross profit margin improved from 10.9% to 12.0%, driven by lower procurement costs and a stronger Renminbi against the US dollar, which reduced the cost of sales.These figures highlight the company's ongoing operational adjustments amid challenging market conditions, while the margin expansion signals improved cost efficiency despite the top-line contraction.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184962434","isCrawlerRequest":true}